Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05836272

Early Administration of Norepinephrine in Sepsis

The management of septic states includes, in addition to the specific treatment (antimicrobials and eradication of the source), a restoration of the hemodynamic disorders and assistance of the failing organs. In general, the restoration of hemodynamic disorders begins first with volume expansion, followed by the use of Noepinephrine (NE) when the target mean arterial pressure (MAP) is not reached after optimizing the intravascular volume. Recently, several studies have supported the interest of early NE on MAP, cardiac output and mortality. It is therefore tempting to restrict fluid administration even in the initial phase of hemodynamic management of severe sepsis by starting NE earlier.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

intensive care unit of the University Hospital Center La Rabta

Tunis, 1007, Tunisia

Location status: Recruiting

Location contact

Ahlem Trifi

CONTACT

[email protected]

+21698692699

About this study

Sepsis is characterized by systemic inflammation induced by a severe infection resulting in an inappropriate host response against that infection. On the microcirculatory scale, vasoplegia with capillary leakage is distinguished. Management of sepsis includes, in addition to specific treatment which includes antimicrobials and eradication of the source, restoration of hemodynamic disorders and assistance to failing organs. In general, the restoration of hemodynamic disorders begins first with volume expansion, followed by the use of vasopressors (mainly norepinephrine: NE as first-line therapy) when the mean arterial pressure target (MAP: reflecting the perfusion pressure organs) is not reached after optimizing the intravascular volume.

Recently, several studies have supported the benefit of administering NE at the start of resuscitation of sepsis. Indeed, its administration at an earlier phase than usually recommended improved MAP and cardiac output with a favorable effect on mortality. At a median interval of 1.3 hours from ICU admission and exclusive administration of NE, MAP was adequately restored within a relatively short time (30 min) and was associated with a better survival rate than that predicted by the severity scores of similar patients from other series reported in the literature. In the recent Thai "CENSER" trial, shock was controlled in 76% of patients in the early NE group versus 48% (p<0.001). On the other hand, the administration of a large quantity of fluids inevitably increases the risk of fluid overload, which is a frequent complication in septic patients. In front of all these arguments, it is therefore tempting to restrict fluid administration even to the initial phase of the hemodynamic management of sepsis by starting NE earlier.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 or older.
  • The patient or his/her legal representative has given informed consent in writing.
  • Diagnosis of sepsis according to the definitions updated by the consensus of sepsis 3.
  • Mean arterial pressure < 65 mmHg

Exclusion criteria

  • Diagnosis of septic shock prior to randomization (where NA requirements exceed those of the trial protocol)
  • Pregnancy,
  • Need for immediate surgery,
  • Neoplasia at an advanced stage
  • Circumstances where water restriction is the rule:
  • Acute pulmonary edema
  • Acute coronary syndrome,

Treatment and study plan

Norepinephrine Bitartrate

Drug

The NE will be prepared as follows: 4 mg mixed with 250 ml of 5% glucose resulting in a final norepinephrine concentration of 0.016 mg/ml. For the control group placebo: 250 ml of 5% glucose will be prepared.

Both drugs will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour, adjusted according to body weight to obtain norepinephrine at 0.05 microgram/kg/min (ie 0.128 to 0.24 mg per hour) in continuous infusion.

Other names: Norepinephrine 0,016 mg/ml

Placebo

Other

For the control group placebo: 250 ml of 5% glucose will be prepared and will be infused via a peripheral line or a venous catheter. The intravenous infusion rate varies from 8 to 15 ml/hour.

Primary outcomes

  1. shock control

    Time frame: within 6 hours

    shock control is defined by a composite criterion (MAP > 65 mm Hg for 2 consecutive measurements and urinary output > 0.5 ml/kg/h for 2 consecutive hours)

Secondary outcomes

  1. Decrease in serum lactate

    Time frame: within 6 hours

    Decrease in serum lactate > 10% from baseline

  2. Volume of fluid

    Time frame: within 48 hours

    Quantity of intravenous fluid received

  3. Mortality

    Time frame: 28 days

    Mortality

Other outcomes

  1. Use of invasive ventilation

    Time frame: 48 hours

    Use of invasive ventilation

  2. Variation of cardiac output

    Time frame: Within 6 hours

    Variation of Cardiac output assessed xith transthoracic cardiac ultrasound (the 15% threshold is considered to define an increase in CO).

Study contacts

Contact information is provided by the study sponsor or research team.

Ahlem Trifi

CONTACT

[email protected]

98692699

Sponsors and collaborators

Lead sponsor

Tunis University

Other

Registry information

Official study title

Early Administration of Norepinephrine in Sepsis (Tunisian Multicenter Randomized Trial)

Acronym: EA-NE-TUN

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
May 1, 2023
Registry last updated
Dec 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.